Earnings per share for the last twelve months: OnKure Therapeutics, Inc. (OKUR)

The rolling annual EPS chart demonstrates the business's resilience to macroeconomic shocks, with the metric fixed at -2.79. OnKure Therapeutics Inc (OKUR) creates high-precision drugs, investing in the development of DNA inhibitors to secure leadership in biopharmaceuticals. A team of elite biologists is attracted by generous funding and the opportunity to work on cutting-edge oncology treatments.
Financial and market metric breakdowns for OnKure Therapeutics Inc (OKUR)

OnKure Therapeutics Inc (OKUR) focuses on developing targeted therapies for precision oncology. The effectiveness of such developments directly impacts the company's bottom line. This metric is calculated by dividing the total annual net income by the number of shares outstanding. It determines the real return on each share of capital, excluding the impact of new issuances. By analyzing the net income per share TTM, an investor assesses the fundamental value of the business.